Photodynamic Therapy in Non-Gastrointestinal Thoracic Malignancies

Kidane, Biniam; Hirpara, Dhruvin H.; Yasufuku, Kazuhiro

doi:10.3390/ijms17010135

Cited by 8 publications

(4 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been approved by FDA for treating cancers like esophageal cancer, non-small cell lung cancer, and skin cancers. It also showed promising results in treating metastasis and local recurrence in clinic trials [ 33 ]. Clearance of microorganisms from blood is also investigated and expanded to microorganisms associated diseases, including HPV associated cervical intraepithelial neoplasia [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

A tissue factor-cascade-targeted strategy to tumor vasculature: a combination of EGFP-EGF1 conjugation nanoparticles with photodynamic therapy

et al. 2016

View full text Add to dashboard Cite

Tumor requires tumor vasculature to supply oxygen and nutrients so as to support its continued growth, as well as provide a main route for metastatic spread. In this study, a TF-cascade-targeted strategy aiming to disrupt tumor blood vessels was developed by combination of TF-targeted HMME-loaded drug delivery system and PDT. PDT is a promising new modality in the treatment of cancers, which employs the interaction between a tumor-localizing photosensitizer and light of an appropriate wavelength to bring about ROS-induced cell death. In vitro results showed that protein EGFP-EGF1modification could significantly contribute to the uptake of nanoparticles by TF over-expressed BCECs. In vivo multispectral fluorescent imaging, the EGFP-EGF1 conjugated nanoparticles showed significantly higher accumulation in tumor tissues than non-conjugated ones. Tumor tissue slides further presented that EGFP-EGF1 conjugated nanoparticles showed significantly higher accumulation in tumor vasculature than non-conjugated ones. In vitro study demonstrated that PDT increased TF expression of BCECs. In vivo imaging, ex vivo imaging and tumor tissue slides showed that PDT further contribute EGFP-EGF1-NP accumulation in tumor. These promising results indicated that PDT enhanced EGFP-EGF1modified PEG-PLGA nanoparticle accumulation in tumor vaculature. Considering that EGFP-EGF1 conjugation enhanced nanoparticles uptake by TF over-expressed endothelium and PDT increased endothelium TF expression. We conclude that PDT triggered a TF cascade targeted effect. A combination of both EGFP-EGF1 modification and PDT provided a positive feed-back target effect to tumor vessels and might have a great potential for tumor therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

A tissue factor-cascade-targeted strategy to tumor vasculature: a combination of EGFP-EGF1 conjugation nanoparticles with photodynamic therapy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Safety of PDT in the use of MPM remains a concern. Intrathoracic PDT has been associated with esophageal fistulas leading to delayed presentation of cough, fever, and lung infiltration requiring surgical intervention …”

Section: Efficacy For Solid Tumorsmentioning

confidence: 99%

“…Intrathoracic PDT has been associated with esophageal fistulas leading to delayed presentation of cough, fever, and lung infiltration requiring surgical intervention. 51 Advances in PDT technology, such as increasing cancer cell selectivity, may be beneficial in future treatment of MPM and are currently being explored in preclinical studies. One such study explores using folate receptor 1 (FOLR1) which has been found to be highly expressed in MPM (79% of MPM samples) to develop FOLR1targeting porphyrin-lipid nanoparticles, resulting in significant cellular damage and apoptosis in vivo.…”

Section: Malignant Pleural Mesotheliomamentioning

confidence: 99%

Photodynamic therapy for solid tumors: A review of the literature

Yanovsky

Bartenstein

Rogers

et al. 2019

Photoderm Photoimm Photomed

173

102

View full text Add to dashboard Cite

Photodynamic therapy (PDT) utilizes a sensitizer agent and light to produce selective cell death. Dermatologists are familiar with PDT for the treatment of actinic keratoses and early nonmelanoma skin cancers, and recent studies have elucidated that PDT has resulted in improved morbidity and secondary outcomes for the treatment of various cancerous and precancerous solid tumors. Light source and dosimetry may be modified to selectively target tissue, and novel techniques such as fractionation, metronomic pulsation, continuous light delivery, and chemophototherapy are under investigation for further optimization of therapy. This article aims to review the expanding indications for PDT and demonstrate the potential of this modality to decrease morbidity and increase quality of life for patients. To illustrate these new indications, we provide a focused review of the latest literature on PDT for dermatologic and other solid tumors including gastrointestinal, peritoneal, lung, genitourinary, brain, breast, and head and neck. Data on efficacy, survival, and side effects vary across tumor types but support PDT for the treatment of numerous solid tumors. With new advances in PDT, indications for this therapeutic modality may expand.

show abstract

“…As a general rule (always with exceptions), the more advanced the cancer at the time of diagnosis, the more aggressive the adjuvant chemotherapy or polychemotherapy that will be applied. Apart from chemotherapy, a number of other treatments are often used, such as immunotherapy and photodynamic therapy . Doroshow and Kumar state that more extensive molecular characterization of tumors and their supporting matrices are anticipated to become standard aspects of oncological practice, which will permit the design of the treatment type for each individual patient and its continuous reevaluation during the course of the treatment.…”

Section: Introductionmentioning

confidence: 99%

Marine Mollusk‐Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance

Ciavatta

Lefranc

Carbone

et al. 2016

Medicinal Research Reviews

View full text Add to dashboard Cite

The chemical investigation of marine mollusks has led to the isolation of a wide variety of bioactive metabolites, which evolved in marine organisms as favorable adaptations to survive in different environments. Most of them are derived from food sources, but they can be also biosynthesized de novo by the mollusks themselves, or produced by symbionts. Consequently, the isolated compounds cannot be strictly considered as “chemotaxonomic markers” for the different molluscan species. However, the chemical investigation of this phylum has provided many compounds of interest as potential anticancer drugs that assume particular importance in the light of the growing literature on cancer biology and chemotherapy. The current review highlights the diversity of chemical structures, mechanisms of action, and, most importantly, the potential of mollusk‐derived metabolites as anticancer agents, including those biosynthesized by mollusks and those of dietary origin. After the discussion of dolastatins and kahalalides, compounds previously studied in clinical trials, the review covers potentially promising anticancer agents, which are grouped based on their structural type and include terpenes, steroids, peptides, polyketides and nitrogen‐containing compounds. The “promise” of a mollusk‐derived natural product as an anticancer agent is evaluated on the basis of its ability to target biological characteristics of cancer cells responsible for poor treatment outcomes. These characteristics include high antiproliferative potency against cancer cells in vitro, preferential inhibition of the proliferation of cancer cells over normal ones, mechanism of action via nonapoptotic signaling pathways, circumvention of multidrug resistance phenotype, and high activity in vivo, among others. The review also includes sections on the targeted delivery of mollusk‐derived anticancer agents and solutions to their procurement in quantity.

show abstract

Photodynamic Therapy in Non-Gastrointestinal Thoracic Malignancies

Cited by 8 publications

References 78 publications

A tissue factor-cascade-targeted strategy to tumor vasculature: a combination of EGFP-EGF1 conjugation nanoparticles with photodynamic therapy

A tissue factor-cascade-targeted strategy to tumor vasculature: a combination of EGFP-EGF1 conjugation nanoparticles with photodynamic therapy

Photodynamic therapy for solid tumors: A review of the literature

Marine Mollusk‐Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance

Contact Info

Product

Resources

About